Bristol-Myers Squibb's Excedrin gains first approval for OTC migraine indication.
This article was originally published in The Tan Sheet
Executive Summary
EXCEDRIN MIGRAINE TO REACH SHELVES BY LATE MARCH: Bristol- Myers Squibb's NDA 20-802 for the new analgesic claim was approved by FDA Jan. 14. The product is the same formulation as the over 20-year-old Excedrin Extra Strength (250 mg aspirin, 250 mg acetaminophen, 65 mg caffeine per dosage unit) and is indicated for "treatment of mild to moderate migraine pain."
You may also be interested in...
Bayer Aspirin Migraine Gets FDA Nod; Midol May Be On Deck
Bayer is expanding the scope of its eponymous aspirin brand from heart attack and stroke prevention to migraine pain
Bayer Aspirin Migraine Gets FDA Nod; Midol May Be On Deck
Bayer is expanding the scope of its eponymous aspirin brand from heart attack and stroke prevention to migraine pain
Bayer Aspirin Migraine Gets FDA Nod; Midol May Be On Deck
Bayer is expanding the scope of its eponymous aspirin brand from heart attack and stroke prevention to migraine pain